The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Splicing mutations predict poorer outcomes with ruxolitinib in myelofibrosis
Francesca Palandri, MD, PhD, University of Bologna, Bologna, Italy, discusses the prognostic significance of splicing mutations in patients with myelofibrosis receiving ruxolitinib. She explains how these mutations are associated with greater cytopenias, poorer treatment outcomes, and reduced survival, and discusses how molecular profiling may help guide earlier use of alternative, disease-modifying therapies. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
